| P50 | author | Alton B. Farris | Q42969934 |
| | Jean Kwun | Q55807308 |
| | Stuart Knechtle | Q56958780 |
| | Janghoon Yoon | Q86715232 |
| P2093 | author name string | F Villinger | |
| | J J Hong | |
| | E Page | |
| | A Gibby | |
| P2860 | cites work | TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease | Q22254041 |
| | Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection | Q28294329 |
| | Extrafollicular antibody responses | Q34212117 |
| | Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates | Q34991139 |
| | Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques | Q36575860 |
| | BAFF is increased in renal transplant patients following treatment with alemtuzumab | Q36925946 |
| | Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. | Q37058039 |
| | Banff 2011 Meeting report: new concepts in antibody-mediated rejection | Q37058043 |
| | The spectrum of antibody-mediated renal allograft injury: implications for treatment | Q37176570 |
| | Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. | Q37308198 |
| | Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys | Q37485481 |
| | Cracking the BAFF code. | Q37517172 |
| | Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection | Q37700827 |
| | Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus | Q38187489 |
| | Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. | Q39904553 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | Significance and implications of capillaritis during acute rejection of kidney allografts | Q43412958 |
| | Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions | Q45342440 |
| | Human leukocyte antigen antibodies and chronic rejection: from association to causation | Q47563762 |
| | Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. | Q47726666 |
| | B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. | Q51890331 |
| | Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. | Q51966554 |
| | An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway | Q57230082 |
| | CADI, Canti, Cavi | Q80112055 |
| | Rituximab therapy for acute humoral rejection after kidney transplantation | Q80318231 |
| | BAFF overexpression is associated with autoantibody production in autoimmune diseases | Q80367249 |
| | Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels | Q81964906 |
| | Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients | Q83149390 |
| | BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection | Q84946422 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 815-822 | |
| P577 | publication date | 2015-02-12 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model | |
| P478 | volume | 15 | |